Core Viewpoint - Intelligent Bio Solutions Inc. has successfully closed a public offering of 1,500,000 shares at a price of $2.00 per share, raising approximately $3.0 million in gross proceeds [1]. Company Overview - Intelligent Bio Solutions Inc. is a medical technology company focused on delivering innovative, rapid, non-invasive testing solutions. The company aims to transform portable testing through its Intelligent Fingerprinting Drug Screening System, which analyzes fingerprint sweat [5]. - The testing system screens for recent drug use, including opiates, cocaine, methamphetamine, and cannabis, and is designed to be hygienic and cost-effective, providing results in under ten minutes [5]. - Current customer segments outside the U.S. include construction, manufacturing, engineering, transport and logistics, drug treatment organizations, and coroners [5]. Offering Details - The public offering included the full exercise of the underwriter's option to purchase an additional 195,652 shares, contributing to the total gross proceeds [1]. - Ladenburg Thalmann & Co. Inc. served as the sole bookrunning manager for the offering [2]. - The offering was conducted under a shelf registration statement filed with the SEC, which was declared effective in April 2022 [3].

Core Viewpoint - Intelligent Bio Solutions Inc. has announced a public offering of 1,304,348 shares of common stock at a price of $2.00 per share, aiming for gross proceeds of approximately $2.6 million before expenses [1][2]. Group 1: Offering Details - The offering is managed by Ladenburg Thalmann & Co. Inc. as the sole bookrunning manager [2]. - The company has granted the underwriter a 45-day option to purchase an additional 195,652 shares at the public offering price [2]. - The offering is expected to close on or about February 21, 2025, subject to customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for working capital and general corporate purposes [3]. Group 3: Company Overview - Intelligent Bio Solutions Inc. specializes in medical technology, focusing on rapid, non-invasive testing solutions [4]. - The company’s Intelligent Fingerprinting Drug Screening System analyzes fingerprint sweat to detect recent drug use, targeting industries such as construction, manufacturing, and transport [4]. - The testing system is designed to be hygienic and cost-effective, providing results in under ten minutes, which is beneficial for safety-critical industries [4].

Company Overview - Intelligent Bio Solutions Inc. is a medical technology company focused on delivering innovative, rapid, non-invasive testing solutions [5] - The company’s Intelligent Fingerprinting Drug Screening System utilizes fingerprint sweat analysis for drug testing, targeting common workplace substances such as opiates, cocaine, methamphetamine, and cannabis [5] - The testing system is designed to be hygienic and cost-effective, providing results in under ten minutes, which is beneficial for employers in safety-critical industries [5] Public Offering Announcement - Intelligent Bio Solutions Inc. has announced the commencement of an underwritten public offering of shares of its common stock, with all shares being offered by the company itself [1] - The offering is subject to market conditions, and there is no assurance regarding the completion, size, or terms of the offering [1] - Ladenburg Thalmann & Co. Inc. is acting as the sole bookrunning manager for this offering, which is made under a shelf registration statement filed with the SEC [2] Regulatory and Contact Information - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and will be available on the SEC's website [3] - Interested parties can obtain copies of the prospectus by contacting Ladenburg Thalmann & Co. Inc. directly [3] - Company contact information includes an email address for inquiries [7] and a dedicated investor and media contact [8]

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 6, 2025 INTELLIGENT BIO SOLUTIONS INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K (State of Incorporation) (Commission File Number) Delaware 001-39825 82-1512711 (IRS employer identification no.) 135 West, 41 Street, 5th Floor New York, NY 10036 (Address of principal execut ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) Commission File Number 001-39825 Intelligent Bio Solutions Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-1512711 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Intelligent Bio Solutions Inc., 135 West, 41 Street, 5FloorNew YorkNY 10036 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: ...

Gross profit increase of 32.6% and 11-point gross profit margin increase driven by higher-margin cartridge sales Submitted FDA 510(k) and remain on track for planned expansion into multi-billion dollar U.S. market in 2025 Added strategic partnerships, increasing visibility across the Asia-Pacific Region and the U.S. Secured 19 accounts during quarter, adding to 400+ active customer accounts in 19 countries NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or t ...

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today issued a letter to shareholders from Harry Simeonidis, President and CEO, reflecting on a year of growth in 2024 and its strategic path forward into the multi-billion dollar U.S. market in 2025. Dear Shareholders, As we begin 2025, I wanted to take the opportunity to recap on the progress we made ...

Avon Freight Group selects INBS’ fingerprint drug testing for three UK sites, reinforcing workplace safety and efficiency INBS surpasses 400+ accounts in 19 countries, targeting aggressive U.S. expansion in 2025 following FDA 510(k) submission UK drug testing market projected to hit $453M by 2030, positioning INBS as a scalable, cost-effective industry leader NEW YORK, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company deli ...

Gross profit expected to surge by 32.6% Unaudited revenue of $0.61 million for fiscal Q2 and $1.48 million for the six months ended December 31, 2024 Higher-margin cartridge sales driving profitability and long-term growth Expanding U.S. and international market presence with FDA submission and strategic partnerships NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive tes ...

Multilingual upgrade will make INBS’ Drug Screening System accessible to over 4 billion users worldwide, including users across the Americas, Europe, Asia and the Middle East, supporting its strategic global expansion goals and planned 2025 entry into the US market.NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced plans for a major upg ...